Abstract 155P
Background
Increased mean platelet volume (MPV), an early marker of platelet activation has been shown to be associated with the pathophysiology of various cancers. However, studies analyzing the prognostic effect of MPV [Disease free survival (DFS) and Overall survival (OS)] in carcinoma stomach are lacking. This study was done to analyze the effect of MPV on DFS and OS of resectable carcinoma stomach patients.
Methods
Retrospective analysis of the data of 143 consecutively resected gastrectomy patients between 2009- 13 was done. Associations between MPV and Clinicopathological factors were assessed. DFS and OS for 5 years were analyzed using the Kaplan-Meier curve.MPV of 10.5 femtolitres (fl) yielded maximum combined sensitivity and specificity on ROC curve. The area under curve(AUC) for MPV was 0.611. Therefore Preoperative cut-off value of MPV was taken as 10.5 fl. Differences between survival curves were tested for statistical significance using the log-rank test.
Results
Mean OS in the group with preoperative MPV < 10.5 vs > 10.5 was 59.3 vs 41.3 mts (95% CI = 58.81 – 60 vs 37.87 - 44.94; P = <0.0001). Mean OS in the group with postoperative (after one month) of MPV< 10.5 vs > 10.5 was 37.9 vs 29.2 mts (95% CI = 32-43.8vs 27.1- 19.8; P = <0.0001). Mean DFS in the group with preoperative MPV < 10.5 vs > 10.5 was 59.8 mts vs 38.2 mts (95% CI = 59.365-60.26 vs 31.798- 44.732; P = <0.0001). Mean DFS with postoperative (after one month) MPV< 10.5 vs > 10.5 58.0 mts vs 25.9 months (95% CI = 56.629 - 59.4 vs 20.841- 30.959; P = 0.012). These results show that MPV estimation both preoperatively and postoperative has a significant impact on both DFS and OS. And those patients who had increased MPV preoperatively had lower DFS and OS compared to those who had MPV lower at the initial presentation. Also, those patients who had initial high MPV which declined postoperatively after one month also had better DFS and OS compared to those who had persistent elevated MPV.
Conclusions
Hence MPV both preoperative and postoperative (1 month) shows to be a promising predictive factor in resectable carcinoma stomach.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
133P - Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
134P - Identification, development and validation of a circulating miRNA-based diagnostic signature for early detection of gastric cancer
Presenter: Daisuke Izumi
Session: Poster display session
Resources:
Abstract
135P - The promising key genes associated with tumour microenvironment and prognosis of hepatocellular carcinoma
Presenter: Jing Fang
Session: Poster display session
Resources:
Abstract
136P - Helicobacter pylori-positive gastric diffuse large B-cell lymphoma: A subset with distinct prognostic features
Presenter: Yuan Cheng
Session: Poster display session
Resources:
Abstract
137P - Significant benefit of pyrotinib combined with SHR6390 in patients with multiline-resistant HER2-positive advanced gastric cancer
Presenter: Zuhua Chen
Session: Poster display session
Resources:
Abstract
138P - Incidence of supracarinal lymph node positivity in operated cases of total esophagectomy: Short term results from a tertiary cancer centre
Presenter: Akhil Palod
Session: Poster display session
Resources:
Abstract
139P - Prognostic usefulness of advanced lung cancer inflammation index in locally-advanced pancreatic carcinoma patients treated with radical chemoradiotherapy
Presenter: Ayberk Besen
Session: Poster display session
Resources:
Abstract
140P - Pancreaticoduodenectomy versus combined neoadjuvant chemotherapy and pancreaticoduodenectomy: Survival patterns among patients with stage II & III periampullary carcinoma
Presenter: Mai Abdelkader
Session: Poster display session
Resources:
Abstract
141P - A 13-gene signature of DNA repair predicts prognosis in gastric cancer patients
Presenter: Jinjia Chang
Session: Poster display session
Resources:
Abstract
142P - Relation between Interleukin -4 (590C/T) gene polymorphism and hepatocellular carcinoma risk in HBV and HCV patients
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract